Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
Total Valuation
Acrivon Therapeutics, Inc. has a market cap or net worth of $68.16M. The enterprise value is -$56.47M.
Market Cap$68.16M
Enterprise Value-$56.47M
Share Statistics
Acrivon Therapeutics, Inc. has 31,555,126 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,555,126
Owned by Insiders44.25%
Owned by Institutions34.78%
Financial Efficiency
Acrivon Therapeutics, Inc.’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -49.44%.
Return on Equity (ROE)-0.46
Return on Assets (ROA)-0.41
Return on Invested Capital (ROIC)-49.44%
Return on Capital Employed (ROCE)-0.50
Revenue Per Employee0.00
Profits Per Employee-1.07M
Employee Count75
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Acrivon Therapeutics, Inc. is ―. Acrivon Therapeutics, Inc.’s PEG ratio is 0.28.
PE Ratio―
PS Ratio0.00
PB Ratio11.51
Price to Fair Value11.51
Price to FCF-29.72
Price to Operating Cash Flow-1.36
PEG Ratio0.28
Income Statement
In the last 12 months, Acrivon Therapeutics, Inc. had revenue of 0.00 and earned -80.56M in profits. Earnings per share was -2.10.
Revenue0.00
Gross Profit-1.01M
Operating Income-89.20M
Pretax Income-80.56M
Net Income-80.56M
EBITDA-79.55M
Earnings Per Share (EPS)-2.10
Cash Flow
In the last 12 months, operating cash flow was -65.79M and capital expenditures -2.28M, giving a free cash flow of -68.06M billion.
Operating Cash Flow-65.79M
Free Cash Flow-68.06M
Free Cash Flow per Share-2.16
Dividends & Yields
Acrivon Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change-67.81%
50-Day Moving Average2.18
200-Day Moving Average1.88
Relative Strength Index (RSI)42.71
Average Volume (3m)996.44K
Important Dates
Acrivon Therapeutics, Inc. upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Acrivon Therapeutics, Inc. as a current ratio of 10.55, with Debt / Equity ratio of 2.32%
Current Ratio10.55
Quick Ratio10.55
Debt to Market Cap<0.01
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Acrivon Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Acrivon Therapeutics, Inc. EV to EBITDA ratio is -25.12, with an EV/FCF ratio of -29.20.
EV to Sales0.00
EV to EBITDA-25.12
EV to Free Cash Flow-29.20
EV to Operating Cash Flow-30.43
Balance Sheet
Acrivon Therapeutics, Inc. has $129.25M in cash and marketable securities with $2.99M in debt, giving a net cash position of $126.27M billion.
Cash & Marketable Securities$129.25M
Total Debt$2.99M
Net Cash$126.27M
Net Cash Per Share$4.00
Tangible Book Value Per Share$0.52
Margins
Gross margin is -107.78%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-107.78%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Acrivon Therapeutics, Inc. is $10.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.00
Price Target Upside362.96% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast21.17%